Abstract The aim of this study was to prepare a dextran-coated layered double hydroxide acetylsalicylic acid (DEX-LDH-ASA) delivery system by co-precipitation of LDH-ASA and its in-situ compositing with DEX. The structure of the system was investigated using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR) and thermogravimetry (TG). Its in vitro drug release properties and in vivo pharmacokinetics in rabbit were also determined. The results show that the DEX-LDH-ASA system retained the crystal structure of LDH-ASA and gave a marked improvement in its dispersion. It also prolonged the release of ASA and shifted the release pattern from first-order to zeroorder kinetics. The pharmacokinetics of ASA administered in the DEX-LDH-ASA system to rabbits produced two absorption peaks with a C max of 14.871.7 mg/L at 2.1170.69 h and an elimination halflife of 2.2570.84 h for the first peak. The fact that delivery of ASA in the DEX-LDH-ASA system was sustained with improved bioavailability indicates the potential of the system as a controlled release formulation with application to other drugs.
Introduction
Traditionally acetylsalicylic acid (ASA) has been used as an antipyretic, analgesic and antiinflammatory drug marketed under the trade name aspirin. Extensive clinical research has shown that ASA is useful in the prevention of cerebral thrombosis, coronary heart disease, myocardial infarction, ischemic stroke, transient ischemic attack, unstable angina and postoperative thrombosis. However, oral administration of ASA is associated with severe irritation to the gastrointestinal tract mucosa leading to a number of adverse effects including nausea, vomiting, ulceration and bleeding. To reduce these adverse effects and maintain or even improve its beneficial effects has led to the development of some oral controlled release systems [1] [2] [3] [4] . Layered double hydroxide (LDH), also known as hydrotalcitelike material or anionic clay, is a supramolecular material consisting of layers of electropositive hydroxides of divalent (M ). Due to the anion exchange properties of LDH, many pharmaceutically active compounds have been intercalated into the interlayer of LDH including anticancer, antiinflammatory, antihypertensive and cardiovascular drugs [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Owing to electrostatic interactions and solid geometry, intercalated drugs are stabilized and usually released in a sustained manner [6] [7] [8] [9] [10] [11] [12] . Early research demonstrated that intercalation of antiinflammatory drugs in the LDH-drug delivery system changed their release profile 7, 8 , improved their solubility and reduced their adverse effects 9 . However, due to the alkalinity of the LDH laminate, the use of orally administered LDHdrug delivery systems still remains somewhat problematic 8 . Dextran (DEX), an α-D-pyran polysaccharide, is a relatively non-toxic, biodegradable and water-soluble macromolecule 16 commonly used as an auxiliary material for colonic targeting of drugs 17 . Its large network of hydroxyl and 1,6-α-glycosidic bonds makes it suitable to provide a protective layer over the LDH-drug system to eliminate the acid corrosion for the LDH laminate [18] [19] [20] . Taking advantage of this, we assembled a supramolecular ASA delivery system composed of LDH loaded ASA with a DEX coating on the surface. The present study was undertaken to elucidate the structure of this DEX-LDH-ASA system and evaluate its in vitro ASA release profile and ASA pharmacokinetics after oral administration in rabbit. 
Materials and methods

Materials
ASA (BR
Instrumentation
Powder X-ray diffraction (XRD) patterns were recorded in the range 5-801 on a Rigaku D/Max-rB diffractometer using Cu K α radiation (λ¼ 0.1542 nm) at 30 kV and 30 mA and a dwell time of 21 per minute. Fourier transform infrared spectra (FT-IR) were recorded in the range 400-4000 cm À 1 on a TENEOR27 IR spectrophotometer (Brooke Company, Germany) with 4 cm À 1 resolution using the KBr disc method. Particle size was determined using a United States PSS NICOMPTM 380 submicron particle size analyzer. Analysis of ASA to determine its loading and release rate was carried out using a Unico UV-3802 UV/VIS spectrophotometer (Unico Instrument Co. Ltd., Shanghai, China). Blood concentrations of SA were determined by HPLC on a HITACHI 2000 HPLC system equipped with an Allsphere ODS column (250 mm Â 4.6 mm, 5 μm) maintained at 25 1C using a mobile phase of methanol:pH 6.8 KH 2 PO 4 buffer (1:3, v/v) at a flow rate of 1 mL/min. Detection was by UV absorption at 240 nm.
Synthesis of the DEX-LDH-ASA system
The intercalated LDH-ASA complex was prepared using the coprecipitation method 8, 13, 18 . An aqueous 2.0 M NaOH solution was added dropwise to 850 mL of an aqueous, magnetically stirred (300 rpm) solution containing MgCl 2 Á 6H 2 O (40.82 g), AlCl 3 Á 6H 2 O (24.30 g) and ASA (72.83 g) maintained at 80 1C under a nitrogen atmosphere. When the pH reached 10.6, the slurry was maintained at 80 1C for a further 30 min to produce the aged slurry. To obtain the solid LDH-ASA complex, the slurry was centrifuged and the solid material collected, washed sequentially with water, ethanol and diethyl ether and finally dried in an oven at 65 1C. The solid product was denoted L 2 (LDH-ASA secondary compound).
An aqueous solution containing 32.20 g dextran in 200 mL deionized water was added to the aged magnetically stirred LDH-ASA slurry prepared as described above. The hot slurry was then poured into 100 mL cold ethanol which was previously maintained at À 80 1C for 24 h to segregate solid with the method of in situ solvent conversion 18, 19 . The ethanol suspension was maintained under a nitrogen atmosphere for 3 h at room temperature before being centrifuged, washed with water and finally dried in an oven at 60 1C. The product was denoted L 3 (DEX-LDH-ASA triple composite).
2.4.
In vitro release of ASA from the LDH-ASA system 2.4.1. Drug loading The L 2 and L 3 samples were powdered in a pestle and mortar and sifted through a 100-mesh screen. Samples (0.2000 g) of powders were then dissolved in the minimum amount of concentrated HCl, transferred to 50 mL volumetric flasks and made up to volume. An aliquot (5 mL) was removed, filtered through a 0.22 μm filter membrane and 2.00 mL of the filtrate diluted to 10.00 mL. The ASA concentration in this solution was then determined from its absorption at 303 nm. All experiments were carried out in triplicate. The results showed that the drug loadings of ASA in L 2 and L 3 were 28.2% and 13.5%, respectively.
Drug release of ASA
Drug release profiles were determined in phosphate buffered saline (PBS, pH 7.50) at 3770.5 1C using a closed circulation system. Before measurement, the system was cleaned by pumping doublydistilled water until the absorbance of the ultraviolet detector remained at zero. After draining the system by operating the pump in the opposite direction for 15 min, 500 mL PBS solution was introduced through a 0.22 μm filter and circulated in the forward direction while the detector was adjusted to zero. A sample (0.2500 mg) of L 2 or L 3 was then added to the dissolution cup and the absorbance and pH monitored for 60 min using a rotation speed of 100 rpm. 
HPLC assay
Plasma concentrations of SA were determined by HPLC using benzoic acid as internal standard (IS) because ASA was ultimately translated into SA in vivo. Stock solutions of SA and benzoic acid (1 mg/mL) were prepared in methanol and diluted to obtain an 0.1 mg/mL SA standard solution and an 0.1 mg/mL working IS solution respectively. Aliquots (500 μL) of blank rabbit plasma were then spiked with SA standard solution to give calibration standards with concentrations of 0.1, 0.5, 1, 2, 4, 10, 16, 24 and 32 mg/mL 1, 4 . Quality control (QC) samples (1, 10 and 60 mg/mL) were prepared in the same way.
Plasma samples were thawed at room temperature and 500 μL aliquots pipetted into Eppendorf tubes. After adding 20 μL aliquots of IS working solution, the mixture was vortex mixed and 200 μL aliquots of monopotassium phosphate buffer (0.5 M filtered through 0.45 μm filters) added. After shaking for 1-2 min, 3 mL ethyl acetate was added and the samples vortexed for 10 min and centrifuged for 15 min at 3000 rpm. Upper organic layers were transferred to clean tubes and the aqueous phase extracted again with 2 mL ethyl acetate. The two extracts were mixed and evaporated to dryness in a vacuum drying oven at 0.8 mPa and 55 1C. Residues were reconstituted in 300 μL monopotassium phosphate solution (0.025 M), vortexed for 10 min and centrifuged at 3000 rpm for 15 min. Finally samples were filtered through 0.22 μm filters and 20 μL aliquots injected into the HPLC system. Concentration of SA was determined from peak areas of analyte and IS.
The assay was linear (C¼ 1.2704þ3.1662 R, r 2 ¼0.9942) with a limit of quantitation of 0.1 mg/L. Results of assay validation for recovery and precision based on QC samples are shown in Table 1 . The results show the method was satisfactory for the determination of SA in biological samples [1] [2] [3] [4] .
Pharmacokinetic analysis
Pharmacokinetic parameters were determined from plasma concentration-time curves using the DAS 2.0 method. The maximum observed concentration (C max ) and time to C max (T max ) were read directly from the data. Areas under plasma concentration-time curves (AUCs) were calculated using the linear trapezoidal rule from time zero to t (AUC 0-t ).
Results and discussion
Characterization of the ASA-loaded LDH delivery system
The X-ray diffraction patterns of L 2 and L 3 are depicted in Fig. 1 . (Fig. 1C, d ¼ 1 .4068 nm) and assigned to the diffraction location of the amorphous organic polymer. This indicates that the organic phase of DEX was actually deposited on the surface of L 2 rather than intercalated into its interlayer spaces. Overall, the results of XRD analysis show that combination with DEX did not change the crystal structure of the LDH-ASA intercalation system. However, modifying the LDH-drug delivery system with organic composites will weaken the ionization of the LDH crystal plane, reduce the toxicity of the loaded drug to biological tissue and improve the cell targeting efficiency of the LDH delivery system 17 . The FT-IR spectra of DEX, L 2 and L 3 are compared in Fig. 2 . DEX showed an intense broad band at 3429.28 cm À 1 which can be assigned to the O-H stretch and the sharp absorption peak (marked with a in Fig. 2A in the supramolecular composite. 18 . In addition, the absorption peaks of intercalated ASA corresponding to ν Ar , δ C-H and ν C-O of ASA (d, e, and f, respectively) of L 2 are found in Fig. 2C at 1575 .08, 1460.35, and 1258.81 cm À 1 respectively. The characteristic vibrations of DEX, including ν C-H and ν C-OH (corresponding to a, b and c) appear at similar locations in Fig. 2C . The spectrum of L 3 shows the specific bands of intercalated ASA, supporting LDH and surface composite DEX but does not appear as a simple superposition of these components indicating L 3 is a supramolecular assembly rather than a simple mixture of DEX, LDH and ASA.
The thermal behavior of L 2 and L 3 nanoparticles was examined using thermogravimetric (TG) and differential thermogravimetric (DTG) analyses. The results are shown in Fig. 3 . Two main thermal events are clearly observed in L 2 (Fig. 3A) . The first occurs in the region 68.5-158.2 1C and is attributed to the removal of adsorbed water on the external surface of LDH and water within the interlayer of L 2 12,13 . This corresponds to a sharp peak in the differential thermogravimetric curve at 115.6 1C with 5.551% weight loss and an enthalpy 46.58 J/g. The second event occurs in the region 272.8-434.9 1C and can be attributed to dehydroxylation of the metal hydroxide layers and decomposition and subtle combustion of intercalated ASA. This corresponds to the strong endothermic peak at 345.9 1C with 18.61% weight loss and an enthalpy of 801.1 J/g. The final stage of weight loss is related to the formation of spinel LDO 9, 16 . Fig. 3B shows that L 3 exhibits more complicated thermal behavior than L 2 and takes place in three major stages of weight loss. These occurred at temperature maxima of 112 1C, 290.3 1C and 425.2 1C with weight losses of 6.476%, 20.02% and 12.32%, respectively, The first stage of weight loss in the range 66.1-168.7 1C can be attributed to the removal of adsorbed and structured water; it displays a temperature interval similar to that seen in L 2 but with an enthalpy value up to 2.75 times higher. This suggests that the elimination of adsorbed water is more difficult in the three-level composite and that the removal of interlaminar water from LDH is also more limited. Compared with L 2 , the mass loss increased by 0.925% in the same temperature range which can be attributed to the partial evaporation of DEX. The second stage of weight loss occurred in the region 209.6-311.4 1C corresponding to a small endothermic section in the DSC curve at 243.3 1C with 9.735% weight loss and an enthalpy of 53.3 J/g. This was followed by another event in the range 331.4-420.1 1C corresponding to a strong broad peak at 373.2 1C with 10.28% weight loss and an enthalpy of 271.4 J/g. The total weight loss of the two successive events (20.02%) was greater than that of L 2 (18.61%) in the region 272.8-434.9 1C but the total enthalpy value (324.7 J/g) was about 40% of L 2 . The variation in slopes of the DSC and DTG curves shows that the dehydroxylation of the metal hydroxide layers and the decomposition of the intercalated ASA is divided into at least two sections which usually overlap during the second stages of weight loss in the LDH-ASA system 9, 16 . It has been suggested that the intercalated material may be involved in the dehydroxylation process of LDH to form spinel LDO via grafting with LDH and replacing hydroxyl groups to promote dehydration, condensation and phase transformation of the hydroxide laminate 5,13 . In the three-level composite, the endothermic enthalpy of decomposition of the LDH laminate decreases and the event is clearly separated from the subsequent thermal decomposition. This demonstrates that ASA intercalated between interlayers of the LDH and the Figure 3 Thermal analysis curves of (A) L 2 and (B) L 3 .
DEX coating outside LDH may both be involved in the dehydroxylation process leading to the dramatic decline in activation energy. The disintegration of the residual solid was also facilitated by the organic functional groups inside and outside the LDH laminate.
The results of particle size determination showed that for L 2 the mean particle diameter was 184.2 nm with a distribution range of 20-354 nm and for L 3 was 54.9 nm with a distribution of 15-68.3 nm. The smaller size and narrower distribution range of L 3 indicates that the dispersion of the ASA-loaded particle is improved by DEX. This is most likely due to the inhibition by DEX of aggregation of the nanoparticles during the drying process 18 .
In vitro release of ASA from the LDH-ASA system
The cumulative release profiles of L 2 and L 3 in PBS (pH 7.50) are compared in Fig. 4 . Release of ASA from L 2 was very rapid with a clear burst effect occurring over 0-4 min and releasing 73.3% of the drug. This is probably due to the reduced barrier to release of drug adsorbed outside the LDH laminate in powder state. This quick release was followed by a slower release over 56 min which occurs by exchange of ASA ions and phosphate ions in the buffer as previously reported 8, 12, 14, 15 . The reduced barrier to drug release also results in a slight burst effect for L 3 but, in this case, only 30% ASA was released over 0-4 min indicating that the majority of drug is encapsulated inside the DEX-LDH-ASA nanocomposite. The release profile of L 3 shows that 45% of the drug was released after 10 min and 100% after 60 min indicating a more controlled release of ASA than from L 2 and that release of ASA from the DEX-LDH-ASA system is significantly reduced by the DEX coating 18, 19 . To gain more insight into the mechanism of release of ASA from L 2 and L 3 , the data were fitted to zero-order and first-kinetic equations. The results shown in Fig. 5 suggest that release is best described by a first-order equation for L 2 (r¼0.9876) and a zero-order equation for L 3 (r¼0.9865). Thus introducing the DEX coating prolongs the release of ASA and shifts the release pattern from first-order to zeroorder. The improved controlled release from the DEX-LDH-ASA system in vitro led us to test its pharmacokinetics in rabbit.
Pharmacokinetics of the DEX-LDH-ASA delivery system in rabbit
The pharmacokinetics of SA produced by ASA hydrolysis after release from the DEX-LDH-ASA system was compared with that produced by ASA itself. Plasma concentration-time profiles and corresponding pharmacokinetic parameters are presented in Table 2 and Fig. 6 . Mean plasma concentrations of ASA over 60 h show that, for ASA administration, the drug concentration rapidly reached a C max of 19.63 mg/L at 1.4 h and then rapidly decreased to a trough level (0.152 mg/L) after 4 h. In contrast, after DEX-LDH-ASA administration, two absorption peaks were clearly observed. The first peak reached a C max of 14.77 mg/L at 2 h after which the concentration dropped slowly to 0.423 mg/L over 10 h and then increased again to 3.455 mg/L at 16 h, finally falling to 0.199 mg/L at 60 h. The results show clearly that the DEX-LDH-ASA system provides slow release of drug in vivo.
Moreover, it appears that oral administration of the DEX-LDH-ASA system produces a higher therapeutic trough plasma concentration, prolongs metabolic process and improves the efficacy of ASA.
There were also clear differences between the other pharmacokinetic parameters. The in vivo absorption half-life, clearance rate and AUC 0 À t after administration of ASA were 0.442 h, 2.269 L/h and 21.15 mg h/L respectively, whereas after administration of the DEX-LDH-ASA system, the half-life of ASA increased by 5.08-fold, the clearance rate reduced by 51% and the oral bioavailability increased by 2.08-fold. In addition, T max was delayed and C max was reduced by 25%. These results show that the DEX-LDH-ASA system improves the bioavailability and decreases the elimination rate of ASA with the potential to increase its efficacy and reduce its adverse effects.
The double peak phenomenon in the pharmacokinetics of ASA administered in the DEX-LDH-ASA system is explicable in terms of its three-level supramolecular characteristics 19 . The DEX coating forms a protective network containing a large number of hydroxyl groups which not only provide an excellent antacid effect [16] [17] [18] , but is also stable enough to proceed down the gastrointestinal tract 14 . In the gastrointestinal environment, rapid release of ASA on the surface together with some in the interlayer results in the first drug peak. The remaining DEX-LDH-ASA and LDH-ASA particles may be involved in enterohepatic recycling Characterization of a DEX-LDH-ASA and its pharmacokinetics in rabbitand return ASA to the blood after transport via the hepatic portal vein leading to the second absorption peak. However, it may also originate from the delayed release of ASA from DEX-LDH-ASA and LDH-ASA nanoparticles in the blood. This would be desirable for a controlled release formulation of ASA to realize its therapeutic effects.
Conclusions
This work shows that a three-level supramolecular delivery system (DEX-LDH-ASA) for ASA can be successfully produced by coating an LDH-ASA complex with DEX. The crystal structure of the LDH-ASA intercalation system was largely maintained in the DEX-LDH-ASA supramolecule as demonstrated by X-ray diffraction, FT-IR spectroscopy and thermal behavior. Our results indicate that the dispersion of ASA-loaded particles and the in vitro and in vivo release of ASA from the LDH-ASA intercalation system were significantly improved. The results also show that the three-stage supramolecular assembly provides superior bioavailability of ASA and reduces its elimination rate. Overall it is clear that the DEX-LDH-ASA system has potential as an orally available controlled release drug delivery system capable of reducing the adverse effects and increasing the therapeutic efficacy of intercalated drugs. Data are expressed as mean7SD, n¼6.
